Evidence map›Paper›PMID 40081955›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2025

Development and Validation of a

Ilke Tunali, Jian Wang, Anupa K Arora, Min Jung Kim, Sergey Shcherbinin, Michael Pontecorvo, Leonardo Iaccarino

Abstract read
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Visual versus quantitative tau-PET Braak staging in Alzheimer's disease using [European journal of nuclear medicine and molecular imaging · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ilke TunaliEli Lilly and Company, Indianapolis, Indiana; and.
Jian WangEli Lilly and Company, Indianapolis, Indiana; and.
Anupa K AroraEli Lilly and Company, Indianapolis, Indiana; and.
Min Jung KimEli Lilly and Company, Indianapolis, Indiana; and.
Sergey ShcherbininEli Lilly and Company, Indianapolis, Indiana; and.
Michael PontecorvoEli Lilly and Company, Indianapolis, Indiana; and.
Leonardo IaccarinoEli Lilly and Company, Indianapolis, Indiana; and iaccarino_leonardo@lilly.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tau PET quantitation methods have been used in research settings and clinical trials to measure tau burden for diagnostic, staging, and prognostic purposes. However, these methods require specialized software, skilled analysts, and advanced image processing. We developed a novel

Indexed as

Alzheimer diseaseflortaucipir PEThigh tauvisual read method

Identifiers

PMID40081955
PMCPMC11960607

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.